2021 American Transplant Congress
Improving Liver Transplantation Outcomes for Hepatitis C Associated Hepatocellular Carcinoma in Direct-Acting Antiviral Therapy Era
Surgery, Westchester Medical Center/New York Medical College, Valhalla, NY
*Purpose: Direct-acting antiviral (DAA) therapy has transformed the outcomes of liver transplantation(LT) in patients with hepatitis C virus (HCV). The aim of this study was…2021 American Transplant Congress
The Role of Histone Acetylation/methylation Mediated Epigenetic Modifications in the Pathogenesis of Non-alcoholic Steatohepatitis-associated Liver Carcinogenesis
*Purpose: Hepatocellular carcinoma (HCC) is one of the most aggressive human cancers and is characterized by an acquisition of multiple abnormal phenotypes driven by epigenetic…2021 American Transplant Congress
Liver Transplantation Following Checkpoint Inhibitor Therapy – Timing is Everything
*Purpose: Use of checkpoint inhibitors (CPI) prior to liver transplantation has not been well studied and limited case reports describe a risk of early graft…2021 American Transplant Congress
Outcomes of Downstaging Hepatocellular Carcinoma (HCC) to within Milan Criteria Before Liver Transplantation (LT): A Multicenter Analysis of the “All-comers” Protocol
*Purpose: Patients with HCC meeting UNOS-downstaging (DS) criteria (1 lesion 5.1-8 cm, 2-3 lesions at least one 3.1-5 cm and total tumor diameter (TTD) ≤8…2021 American Transplant Congress
Albumin Level Prior to Liver-Directed Therapy is a Risk Factor of Waitlist Tumor Progression Independent of HCC Burden
Ochsner Health, New Orleans, LA
*Purpose: Milan Criteria, α-fetoprotein (AFP), and MELD score at diagnosis influence prognosis in bridge to transplant (BTT) hepatocellular carcinoma (HCC). With HCC surveillance many patients…2021 American Transplant Congress
Role of Baseline PD-1 Checkpoint Inhibitor Pathway Expression in Bridge to Liver Transplant Hepatocellular Carcinoma
Ochsner Health, New Orleans, LA
*Purpose: Response to first line liver-directed therapy (LDT) in hepatocellular carcinoma (HCC) has important implications in both bridge to transplant (BTT) success as well as…2021 American Transplant Congress
Short Waiting Time is Not Associated with Decrease in Disease-free Survival in Liver Transplant Recipients with HCC
*Purpose: Studies have suggested that shorter waiting times (WT) for liver transplant (LT) in patients with hepatocellular carcinoma (HCC) may be associated with increased HCC…2021 American Transplant Congress
NASH-Related HCC is Associated with Lower Rates of Post-Transplant HCC Recurrence: A Large Database Analysis
Department of Surgery, Thomas Jefferson University, Philadelphia, PA
*Purpose: As incidence of hepatocellular carcinoma (HCC) and Non-Alcoholic Steatohepatitis (NASH) increase, NASH-related HCC is an increasingly common transplant indication. Large-scale studies evaluating transplantation for…2021 American Transplant Congress
Outcomes of DCD Allografts in Liver Transplant Recipients with HCC
*Purpose: Early studies demonstrated inferior survival for liver transplant (LT) recipients with hepatocellular carcinoma (HCC) who received allografts from donation after cardiac death (DCD) donors…2021 American Transplant Congress
Adjuvant Immunotherapy for Liver Transplant Recipients with Hepatocellular Carcinoma Using Donor Liver-derived Natural Killer Cells
1Hiroshima University, Hiroshima, Japan, 2University of Miami, Miami, FL
*Purpose: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and is an indication for liver transplantation (LT). Immunosuppressive regimens currently used after…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 23
- Next Page »